Insight

Federica Giugliano: Characteristics and treatment patterns of patients with high risk HR+ BC in CANTO cohort

Photo of Federica Guigliano from www.vjoncology.com

Dec 4, 2024, 08:01

Federica Giugliano: Characteristics and treatment patterns of patients with high risk HR+ BC in CANTO cohort

Federica Giugliano, ESMO Translational Research Fellow at Gustave Roussy, shared a post on X:

“Published in ESMO Open our latest article, describing characteristics and treatment patterns of patients with high risk HR+ BC in CANTO cohort.

Thanks to all the authors, especially to Elie Rassy and Barbara Pistilli.”

Characteristics, treatment patterns and survival of patients with high-risk early hormone receptor-positive breast cancer in French real-world settings: an exploratory study of the CANTO cohort

Authors: F. Giugliano, A. Bertaut, J. Blanc, A.-L. Martin, C. Gaudin, M. Fournier, A. Kieffer, B. Sauterey, C. Levy, M. Campone, C. Tarpin, F. Lerebours, M.-A. Mouret-Reynier, G. Curigliano, F. André, B. Pistilli, E. Rassy

Federica Giugliano: Characteristics and treatment patterns of patients with high risk HR+ BC in CANTO cohort

A. Bertaut A. Kieffer A.-L. Martin B. Pistilli B. Sauterey Barbara Pistilli C. Gaudin C. Levy C. Tarpin cancer CANTO cohort E. Rassy Elie Rassy ESMO Open F. André F. Giugliano F. Lerebours Federica Giugliano G Curigliano J. Blanc M. Campone M. Fournier M.-A. Mouret-Reynier OncoDaily Oncology

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage